About Invivyd
Invivyd is a company based in Waltham (United States) founded in 2022. The company has 99 employees as of December 31, 2024. Invivyd offers products and services including Antibody Therapies and Invymab. Invivyd operates in a competitive market with competitors including Blue Rock Therapeutics, Impel Pharmaceuticals, CellCarta, Ascend and RiboPro, among others.
- Headquarter Waltham, United States
- Employees 99 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Invivyd, Inc.
-
Annual Revenue
$25.38 M (USD)0as on Dec 31, 2024
-
Net Profit
-$169.93 M (USD)14.46as on Dec 31, 2024
-
EBITDA
-$173.76 M (USD)15.55as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
99
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Invivyd
Invivyd is a publicly listed company on the NASDAQ with ticker symbol IVVD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Invivyd
Invivyd offers a comprehensive portfolio of products and services, including Antibody Therapies and Invymab.
Monoclonal antibodies for preventing and treating viral diseases.
Antibody-based solutions targeting evolving viral threats.
People of Invivyd
Unlock access to complete
Unlock access to complete
Leadership Team
15 people
Legal and Compliance
2 people
Human Resources and Administration
2 people
Data Analysis and Operations Team
2 people
Software Development Team
2 people
Product Management Team
2 people
Principal Team
1 people
Consultant Team
1 people
Unlock access to complete
Funding Insights of Invivyd
Detailed funding history for Invivyd
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Invivyd
Investment portfolio details for Invivyd
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Invivyd
Detailed financials for Invivyd
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Invivyd Comparisons
Peer comparison for Invivyd
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Invivyd
Invivyd operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Blue Rock Therapeutics, Impel Pharmaceuticals, CellCarta, Ascend and RiboPro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Stem cell therapies are developed for cardiovascular and neurological diseases.
|
|
| Locked | Locked | Locked |
Transformative therapies are developed and commercialized through specialized services.
|
|
| Locked | Locked | Locked |
Histopathology and genomics services are offered by the CRO.
|
|
| Locked | Locked | Locked |
Online insurance payments and premium financing are enabled for businesses.
|
|
| Locked | Locked | Locked |
Online supplier and developer of RNA based products
|
Detailed competitors of Invivyd
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Invivyd
Complete news archive for Invivyd
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Invivyd
Invivyd was founded in 2022.
Invivyd is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
As of Dec 31, 2024, the latest employee count at Invivyd is 99.
Annual revenue of Invivyd is $25.38M as on Dec 31, 2024.
Invivyd was founded in 2022 and is based in Waltham, United States. Drug research and development activities are focused on stem cell targets, alongside clinical trial services within the biotechnology sector. Operations emphasize pharmaceutical innovation through specialized RD support. The board is chaired by Marc Elia, with Ajay Royan serving as a director.
Invivyd's top competitors include Blue Rock Therapeutics, Ascend and CellCarta.
Invivyd offers Antibody Therapies and Invymab.
Yes, Invivyd is publicly traded on NASDAQ under the ticker symbol IVVD.
The ticker symbol of Invivyd is IVVD on NASDAQ.